Raloxifene elicits combined rapid vasorelaxation and long-term anti-inflammatory actions in rat aorta

Journal of Pharmacology and Experimental Therapeutics

Volumn 319, Issue 3, 2006, Pages 1444-1451

  Pinna, Christian ^a   Bolego, Chiara ^a   Sanvito, Paola ^a,b   Pelosi, Valeria ^a,b   Baetta, Roberta ^a   Corsini, Alberto ^a   Gaion, Rosa Maria ^b   Cignarella, Andrea ^a,b  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF PADOVA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; FULVESTRANT; LIPOPOLYSACCHARIDE; METHYLPIPERIDINO PYRAZOLE; RALOXIFENE; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; AORTA; AORTA MEDIA; ARTICLE; CELL VIABILITY; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ESTROGEN THERAPY; FEMALE; MALE; NONHUMAN; OVARIECTOMY; PRIORITY JOURNAL; PROTEIN SYNTHESIS; RAT; SMOOTH MUSCLE FIBER; VASCULAR RING; VASODILATATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; AORTA, THORACIC; BLOTTING, WESTERN; CELL SURVIVAL; ESTRADIOL; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA; FEMALE; ISOMETRIC CONTRACTION; KINETICS; LIPOPOLYSACCHARIDES; MUSCLE RELAXATION; MUSCLE, SMOOTH, VASCULAR; NITRITES; OVARIECTOMY; RALOXIFENE; RATS; SELECTIVE ESTROGEN RECEPTOR MODULATORS;

EID: 33751178013     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.106.106062     Document Type: Article

References (44)

1. Barchiesi F, Jackson EK, Imthurn B, Fingerle J, Gillespie DG, and Dubey RK (2004) Differential regulation of estrogen receptor subtypes α and β in human aortic smooth muscle cells by oligonucleotides and estradiol. J Clin Endocrinol Metab 89:2373-2381.
2. Barkhem T, Carlsson B, Nilsson Y, Enmark E, Gustafsson JÅ, and Nilsson S (1998) Differential response of estrogen receptor α and estrogen receptor β to partial estrogen agonists/antagonists. Mol Pharmacol 54:105-112.
3. Barrett-Connor E, Grady D, Sashegyi A, Anderson PW, Cox DA, Hoszowski K, Rautaharju P, and Harper KD for the MORE Investigators (2002) Raloxifene and cardiovascular events in osteoporotic postmenopausal women: four-year results from the MORE (Multiple Outcomes of Raloxifene Evaluation) randomized trial. J Am Med Assoc 287:847-857.
4. Barrett-Connor E, Mosca L, Collins P, Geiger MJ, Grady D, Kornitzer M, McNabb MA, and Wenger NK for the Raloxifene Use for The Heart (RUTH) Trial Investigators (2006) Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med 355:125-137.
5. Bjarnason NH, Haarbo J, Byrjalsen I, Alexandersen P, Kauffman RF, and Christiansen C (2001) Raloxifene and estrogen reduces progression of advanced atherosclerosis: a study in ovariectomized, cholesterol-fed rabbits. Atherosclerosis 154:97-102.
6. Bolego C, Cignarella A, Sanvito P, Pelosi V, Pellegatta F, Puglisi L, and Pinna C (2005) The acute estrogenic dilation of rat aorta is mediated solely by selective estrogen receptor-α agonists and is abolished by estrogen deprivation. J Pharmacol Exp Ther 313:1203-1208.
7. Bolego C, Cignarella A, Zancan V, Pinna C, Zanardo R, and Puglisi L (1999) Diabetes abolishes the vascular protective effects of estrogen in female rats. Life Sci 64:741-749.
8. Bolego C, Vegeto E, Pinna C, Maggi A, and Cignarella A (2006) Selective agonists of estrogen receptor isoforms - new perspectives for cardiovascular disease. Arterioscler Thromb Vasc Biol 26:2192-2199.
9. Bracamonte MP, Rud KS, and Miller VM (2002) Mechanism of raloxifene-induced relaxation in femoral veins depends on ovarian hormonal status. J Cardiovasc Pharmacol 39:704-713.
10. Brzozowski AM, Pike ACW, Dauter Z, Hubbard RE, Bonn T, Engström O, Öhman L, Greene GL, Gustafsson JÅ, and Carlquist M (1997) Molecular basis of agonism and antagonism in the oestrogen receptor. Nature (Lond) 389:753-758.
11. Cao C, Matsumura K, Yamagata K, and Watanabe Y (1995) Induction by lipopolysaccharide of cyclooxygenase-2 mRNA in rat brain; its possible role in the febrile response. Brain Res 697:187-196.
12. 2+ influx. J Pharmacol Exp Ther 312:1266-1271.
13. Chen Z, Yuhanna IS, Galcheva-Gargova Z, Karas RH, Mendelsohn ME, and Shaul PW (1999) Estrogen receptor α mediates the nongenomic activation of endothelial nitric oxide synthase by estrogen. J Clin Investig 103:401-406.
14. Cignarella A, Bolego C, Pinna C, Zanardo R, Nardi F, Zancan V, and Puglisi L (2000) Androgen deprivation, estrogen treatment and vascular function in male rat aorta. Naunyn-Schmiedeberg's Arch Pharmacol 361:166-172.
15. Cignarella A, Minici C, Bolego C, Pinna C, Sanvito P, Gaion RM, and Puglisi L (2006) Potential pro-inflammatory action of resveratrol in vascular smooth muscle cells from normal and diabetic rats. Nutr Metab Cardiovasc Dis 16:322-329.
16. Dudley MW, Sheeler CQ, Wang H, and Khan S (2000) Activation of the human estrogen receptor by the antiestrogens ICI 182,780 and tamoxifen in yeast genetic systems: implications for their mechanism of action. Proc Natl Acad Sci USA 97:3696-3701.
17. Esposito E, Iacono A, Raso GM, Pacilio M, Coppola A, Di Carlo R, and Meli R (2005) Raloxifene, a selective estrogen receptor modulator, reduces carrageenan-induced acute inflammation in normal and ovariectomized rats. Endocrinology 146:3301-3308.
18. Evans MJ, Lai K, Shaw LJ, Harnish DC, and Chadwick CC (2002) Estrogen receptor α inhibits IL-1β induction of gene expression in the mouse liver. Endocrinology 143:2559-2570.
19. Figtree GA, Lu Y, Webb CM, and Collins P (1999) Raloxifene acutely relaxes rabbit coronary arteries in vitro by an estrogen receptor-dependent and nitric oxide-dependent mechanism. Circulation 100:1095-1101.
20. Figtree GA, Webb CM, and Collins P (2000) Tamoxifen acutely relaxes coronary arteries by an endothelium-, nitric oxide-, and estrogen receptor-dependent mechanism. J Pharmacol Exp Ther 295:519-523.
21. Haynes MP, Sinha D, Russell KS, Collinge M, Fulton D, Morales-Ruiz M, Sessa WC, and Bender JR (2000) Membrane estrogen receptor engagement activates endothelial nitric oxide synthase via the PI3-kinase-Akt pathway in human endothelial cells. Circ Res 87:677-682.
22. Idel S, Ellinghaus P, Wolfrum C, Nofer JR, Gloerich J, Assmann G, Spener F, and Seedorf U (2002) Branched chain fatty acids induce nitric oxide-dependent apoptosis in vascular smooth muscle cells. J Biol Chem 277:49319-49325.
23. Kim HP, Lee JY, Jeong JK, Bae SW, Lee HK, and Jo I (1999) Nongenomic stimulation of nitric oxide release by estrogen is mediated by estrogen receptor α localized in caveolae. Biochem Biophys Res Commun 263:257-262.
24. Lapchak PA (1991) Effect of estradiol treatment on β-endorphin content and release in the female rat hypothalamus. Brain Res 554:198-202.
25. 2+ influx. Am J Physiol 289:F137-F144.
26. Longo M, Brama M, Marino M, Bernardini S, Korach KS, Wetsel WC, Scandurra R, Faraggiana T, Spera G, Baron R, et al. (2004) Interaction of estrogen receptor α with protein kinase C α and c-Src in osteoblasts during differentiation. Bone (NY) 34:100-111.
27. Maggi A, Cignarella A, Brusadelli A, Bolego C, Pinna C, and Puglisi L (2003) Diabetes undermines estrogen control of inducible nitric oxide synthase function in rat aortic smooth muscle cells through overexpression of estrogen receptor-β. Circulation 108:211-217.
28. Mercier I, Mader S, and Calderone A (2003) Tamoxifen and ICI 182,780 negatively influenced cardiac cell growth via an estrogen receptor-independent mechanism. Cardiovasc Res 59:883-892.
29. Morello KC, Wurz GT, and DeGregorio MW (2003) Pharmacokinetics of selective estrogen receptor modulators. Clin Pharmacokinet 42:361-372.
30. Pike ACW, Brzozowski AM, Hubbard RE, Bonn T, Thorsell AG, Engström O, Ljunggren J, Gustafsson JÅ, and Carlquist M (1999) Structure of the ligand-binding domain of oestrogen receptor beta in the presence of a partial agonist and full antagonist. EMBO (Eur Mol Biol Organ) J 18:4608-4618.
31. Rahimian R, Dubé GP, Toma W, Dos Santos N, McManus BM, and van Breemen C (2002) Raloxifene enhances nitric oxide release in rat aorta via increasing endothelial nitric oxide mRNA expression. Eur J Pharmacol 434:141-149.
32. Staub C, Rauch M, Ferriere F, Trepos M, Dorval-Coiffec I, Saunders PT, Cobellis G, Flouriot G, Saligaut C, and Jegou B (2005) Expression of estrogen receptor ESR1 and its 46-kDa variant in the gubernaculum testis. Biol Reprod 73:703-712.
33. Sun J, Huang YR, Harrington WR, Sheng S, Katzenellenbogen JA, and Katzenellenbogen BS (2002) Antagonists selective for estrogen receptor α. Endocrinology 143:941-947.
34. Sunday L, Tran MM, Krause DN, and Duckles SP (2006) Estrogen and progestogens differentially modulate vascular proinflammatory factors. Am J Physiol 291:E261-E267.
35. Suuronen T, Nuutinen T, Huuskonen J, Ojala J, Thornell A, and Salminen A (2005) Anti-inflammatory effect of selective estrogen receptor modulators (SERMs) in microglial cells. Inflamm Res 54:194-203.
36. Takahashi K, Ohmichi M, Yoshida M, Hisamoto K, Mabuchi S, Arimoto-Ishida E, Mori A, Tsutsumi S, Tasaka K, Murata Y, et al. (2003) Both estrogen and raloxifene cause G1 arrest of vascular smooth muscle cells. J Endocrinol 178:319-329.
37. 2+ channels. Stroke 35:1709-1714.
38. Vegeto E, Belcredito S, Etteri S, Ghisletti S, Brusadelli A, Meda C, Krust A, Dupont S, Ciana P, Chambon P, et al. (2003) Estrogen receptor-α mediates the brain antiinflammatory activity of estradiol. Proc Natl Acad Sci USA 100:9614-9619.
39. Vo PA, Lad B, Tomlinson JA, Francis S, and Ahluwalia A (2005) Autoregulatory role of endothelium-derived nitric oxide (NO) on lipopolysaccharide-induced vascular inducible NO synthase expression and function. J Biol Chem 280:7236-7243.
40. Wakeling AE, Dukes M, and Bowler J (1991) A potent specific pure antiestrogen with clinical potential. Cancer Res 51:3867-3873.
41. Wassmann S, Laufs U, Stamenkovic D, Linz W, Stasch JP, Ahlbory K, Rösen R, Böhm M, and Nickenig G (2002) Raloxifene improves endothelial dysfunction in hypertension by reduced oxidative stress and enhanced nitric oxide production. Circulation 105:2083-2091.
42. Weihua Z, Andersson S, Cheng G, Simpson ER, Warner M, and Gustafsson JÅ (2003) Update on estrogen signaling. FEBS Lett 546:17-24.
43. Zancan V, Santagati S, Bolego C, Vegeto E, Maggi A, and Puglisi L (1999) 17β-estradiol decreases nitric oxide synthase II synthesis in vascular smooth muscle cells. Endocrinology 140:2004-2009.
44. Zheng H, Kangas L, and Harkonen PL (2004) Comparative study of the short-term effects of a novel selective estrogen receptor modulator, ospemifene, and raloxifene and tamoxifen on rat uterus. J Steroid Biochem Mol Biol 88:143-156.